Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Egypt / NCT03647072
Recruiting Phase 3

PPI Versus Histamine Antagnists as Adjuvant to Chemotherapy

NCT03647072 · tracked via the Priya Life Science Egypt tracker
Sponsor
Sherief Abd-Elsalam
Phase
Phase 3
Started
2018-08-01
Last updated
2018-08-27

Condition(s) studied

Lymphoma

Investigational drug(s) / intervention(s)

CHOP →CHOP Plus Lanzoprazole →CHOP Plus FamotidineAll CHOP trials (10) →All Famotidine trials (6) →

CHOP: CHOP only

CHOP Plus Lanzoprazole: CHOP plus Lanzoprazole 60 mg

CHOP Plus Famotidine: CHOP Plus Famotidine 40 mg

Study summary

The study is a Comparative Clinical and Biochemical Study Evaluating the effect of Proton Pump I nhibitors versus histamine 2 Receptor antagonists as an adjuvant with chemotherapy in patients with Non-hodgkin Lymphoma.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * DLBCL Lymphoma subtype --No comorbid disease Exclusion Criteria: * Pregnancy * Peptic ulcer * Severe cardiac disease * Osteoporosis

Primary outcome measure(s)

  • Number of patients eith radiological and clinical improvement — 6 months
    Number of patients eith radiological and clinical improvement after cycles of chemotherapy

Trial sites (1)

FacilityCityRegionStatus
Sherief Abd-Elsalam Cairo Egypt Recruiting

More Sherief Abd-Elsalam trials in Egypt

Statins and ARBs on Rheumatoid Activity Recruiting
Role of Point of Care Ultrasound in Endotracheal Tube Placement Recruiting
Effect of Some Drugs on Rheumatoid Arithritis Activity Recruiting
Effect of Some Drugs on Liver Fibrosis Recruiting
Role of Bumetanide in Treatment of Autism Recruiting

Other trials for the same condition

Metabolic Insights: the Impact of F-18 FDG PET/CT in Adult Lymphoma Starting soon
RT or No RT Following Chemotherapy in Treating Patients With Stage III/IV Hodgkin's Disease Active, not recruiting
A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03647072 on ClinicalTrials.gov ↗ ← All trials in Egypt